/ Unknown statusPhase 1/2IIT Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies
CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.
/ Unknown statusPhase 1/2IIT Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19
The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv. All participants will receive autologous chimeric antigen receptor engineered T cells.
100 Clinical Results associated with Icartab Biotechnology Co Ltd.
0 Patents (Medical) associated with Icartab Biotechnology Co Ltd.
100 Deals associated with Icartab Biotechnology Co Ltd.
100 Translational Medicine associated with Icartab Biotechnology Co Ltd.